Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, São Paulo, Brazil; Department of Biomedical Sciences, Faculty of Health Sciences, University of Talca (UTALCA), Talca, Maule Region, Chile; Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, São Paulo, Brazil; Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
Oral Oncol. 2017 Sep;72:38-47. doi: 10.1016/j.oraloncology.2017.07.003. Epub 2017 Jul 12.
Over the years, several tumor biomarkers have been suggested to foresee the prognosis oral squamous cell carcinoma (OSCC) patients. Here, we present a systematic review to identify, evaluate and summarize the evidence for OSCC reported markers. Eligible studies were identified through a literature search of MEDLINE/PubMed until January 2016. We included primary articlesreporting overall survival, disease-free survival and cause-specific survival as outcomes. Our findings were analysed using REporting recommendations for tumor MARKer prognostic studies (REMARK), QuickGo tool and SciCurve trends. We found 41 biomarkers, mostly proteins evaluated by immunohistochemistry. The selected studies are of good quality, although, any study referred to a sample size determination. Considering the lack of follow-up studies, the molecules are still potential biomarkers. Further research is required to validate these biomarkers in well-designed clinical cohort-based studies.
多年来,已经有几种肿瘤生物标志物被提出用于预测口腔鳞状细胞癌(OSCC)患者的预后。在这里,我们进行了一项系统综述,以确定、评估和总结 OSCC 报告标志物的证据。通过对 MEDLINE/PubMed 数据库的文献检索,我们确定了符合条件的研究,检索时间截至 2016 年 1 月。我们纳入了报告总生存、无病生存和特定原因生存作为结局的原始文章。我们使用报告肿瘤标志物预后研究的推荐意见(REMARK)、QuickGo 工具和 SciCurve 趋势对我们的发现进行了分析。我们发现了 41 种生物标志物,主要是通过免疫组织化学评估的蛋白质。所选研究的质量较好,但任何研究都涉及到样本量的确定。考虑到缺乏随访研究,这些分子仍然是潜在的生物标志物。需要进一步的研究来在基于设计良好的临床队列研究中验证这些生物标志物。